An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business
The multibillion-dollar business for immunoglobin products is dominated by three key players: CSL, Shire and Grifols. And one of them recently invested $50 million in a South San Francisco-based biotech that thinks it has a key to disrupting the entire global market.
The company is a little known private player called GigaGen. It has all of 10 staffers who are now so closely packed into their work space that the company will have to find new digs to expand into. But it has global ambitions to do something completely new in polyclonal antibodies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.